Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of HZN-825 in diffuse cutaneous systemic sclerosis
MOH_2023-04-25_012572Phase 2Recruiting
- Sponsor
- Horizon Therapeutics
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fipaxalparant in systemic sclerosis (SSc), sponsored by Horizon Therapeutics. Started Mar 2023; status: recruiting.
02
Drugs
fipaxalparant
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2023-04-25_012572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-25_012572.